Jiangsu Lianhuan Pharmaceutical (600513.SH): Bilastine API Approved for Marketing

date
15:36 19/11/2026
avatar
GMT Eight
Jiangsu Lianhuan Pharmaceutical (600513.SH) announced that the company recently received the "Chemical API Marketing Application Approval Notice" issued by the National Medical Products Administration for the API bilastine. Bilastine is a non-sedating, long-acting antihistamine that selectively antagonizes peripheral H1 receptors, with no affinity for muscarinic receptors and low affinity for other receptors.
Jiangsu Lianhuan Pharmaceutical (600513.SH) announced that the company recently received the "Chemical API Marketing Application Approval Notice" for the API bilastine issued by the National Medical Products Administration. Bilastine is a non-sedating, long-acting antihistamine that selectively antagonizes peripheral H1 receptors, has no affinity for muscarinic receptors, and has low affinity for other receptors. The company's receipt of the "Chemical API Marketing Application Approval Notice" for bilastine API indicates that the API has passed review and approval, complies with the relevant requirements of domestic drug registration regulations, and is conducive to enriching the company's product line.